Table 1 Characteristics of patients in eligible studies
Trial | Year | No. of Patients | Follow-up (months) | DAPT (Months) | O-DES Characteristics | DP-DES Characteristics | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
O-SES | DP-DES | Stent | Thickness | Drug | Stent | Thickness | Drug | ||||
BIO-RESORT | 2016 | 1169 | 1173 | 12 | 6 | Orsiro | 60 | Sirolimus | Resolute Integrity | 91 | zotarolimus |
BIOFLOW II | 2015 | 298 | 154 | 12 | > 6 | Orsiro | 60 | Sirolimus | Xience Prime | 81 | Everolimus |
BIOFLOW V | 2017 | 884 | 450 | 12 | > 6 | Orsiro | 60 | Sirolimus | Xience Prime | 81 | Everolimus |
BIOSCIENCE | 2016 | 1063 | 1056 | 12 | 12 | Orsiro | 60 | Sirolimus | Xience Prime | 81 | Everolimus |
ORIENT | 2017 | 250 | 122 | 12 | > 12 | Orsiro | 60 | Sirolimus | Resolute Integrity | 91 | zotarolimus |
PRISON IV | 2017 | 165 | 165 | 12 | > 12 | Orsiro | 60 | Sirolimus | Xience Prime | 81 | Everolimus |